In an ACE2-deficient environment, SARS-CoV-2 entry into cells induces further downregulation of ACE2, amplifying the adverse effects of the ACE/AngII/AT1 axis and attenuating the beneficial effects of the ACE2/Ang1-7 (Angiotensin1-7) /mas axis, leading to cardiomyocyte fibrosis, endothelial damage, mediating inflammatory responses and vasoconstriction, and accelerating cardiovascular diseases such as hypertension and heart failure’s further progression (Verdecchia et al., 2020; García-Escobar et al., 2021). Here, ACE2 is linked to heart failure.